Search
Organon & Co
OGNAdd to Watchlist
13.550USD
+0.005+0.04%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.56BMarket Cap
14.35P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Organon & Co is 5.67, ranking 138 out of 155 in the Pharmaceuticals industry. The average price target is 9.00, with a high of 12.00 and a low of 5.00.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
10.800
Target Price
-20.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Organon & Co
OGN
6
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Organon & Co's expected revenue for the next quarter?
Organon & Co's expected revenue is 1.57B.
What is Organon & Co's price target?
Analysts forecast that Organon & Co's price target is USD 9.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 5.00.
How have Organon & CoOGN's recent earnings per share performed?
The market expectation was USD 0.41, while Organon & CoOGN's earnings per share (EPS) for the previous quarter was USD 0.56. EPS for the next quarter is expected at USD 0.94.
What is the analyst rating for Organon & Co?
Based on the ratings of Organon & Co's stock from 6 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.